Premium
Clinical significance of anti‐annexin V antibodies in patients with systemic lupus erythematosus
Author(s) -
Kaburaki Junichi,
Kuwana Masataka,
Yamamoto Mihoko,
Kawai Shinichi,
Ikeda Yasuo
Publication year - 1997
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199703)54:3<209::aid-ajh6>3.0.co;2-#
Subject(s) - medicine , antibody , clinical significance , systemic lupus , immunology , annexin , systemic disease , lupus erythematosus , immunopathology , disease , flow cytometry
Annexin V has a calcium‐dependent binding affinity for anionic phospholipids and activated platelets, and prevents prothrombinase activity. We investigated the clinical significance of IgG anti‐annexin V antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera were examined for IgG anti‐annexin V antibodies by ELISA. IgG anti‐annexin V antibodies were detected in 27 of 140 patients (19%). Significantly higher incidences of arterial or venous thrombosis, intrauterine fetal loss, and prolonged activated partial thromboplastin time were found in patients with anti‐annexin V antibodies than in those without anti‐annexin V antibodies. Three patients with thrombosis were found not to have anticardiolipin antibodies, but to show sustained serological reactions for anti‐annexin V antibodies, irrespective of prednisolone administration. These results indicated the clinical characteristics of SLE patients with anti‐annexin V antibodies, and that these antibodies may be associated with the pathogenesis of thrombotic events. Am. J. Hematol. 54:209–213, 1997 © Wiley‐Liss, Inc.